Your session is about to expire
← Back to Search
Bevacizumab + Doxorubicin + Radiation for Sarcoma
Study Summary
This trial is testing the safety of the combination of bevacizumab with doxorubicin and radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 4 trial • 45 Patients • NCT02036424Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a primary or locally recurrent soft tissue sarcoma and I haven't had radiation before.I have not had a heart attack or any heart procedures in the last 6 months.My primary tumor is at least 5 cm wide or I have a local recurrence of any size.I have not had major surgery in the last 4 weeks.I have a condition that makes my blood clot more than normal.I have a history of blood clots in my veins or lungs.My sarcoma is confirmed to be of intermediate or high severity.I am currently taking blood thinners.A specialist has confirmed my sarcoma can be surgically removed.My cancer has spread to other parts of my body.I have previously been treated with doxorubicin or similar drugs.I have a bleeding disorder.I haven't had any cancer treatment in the last 4 weeks.I do not have any unmanaged ongoing illnesses.
- Group 1: Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this an innovative medical experiment?
"Currently, Bevacizumab is the subject of 701 active trials conducted in multiple cities and countries around the world. The first clinical investigation was launched by Alfacell back in 1997; this trial included 300 participants over its Phase 3 evaluation period. Since then, 1747 separate experiments have been performed with regards to this drug."
How many individuals are currently participating in this investigation?
"This research study is not presently accepting participants. It was launched on March 1st 2013 and last updated on April 6th 2022. For those looking for other studies, 443 trials are actively searching for sarcoma patients, while 701 studies offer Bevacizumab as a potential therapy."
For what medical issues is Bevacizumab commonly prescribed?
"Bevacizumab is a proven treatment for recurrent platinum-sensitive epithelial ovarian cancer and can also be helpful in managing malignant neoplasms, persistent cervical cancer, and Kaposi's sarcoma related to AIDS."
Has Bevacizumab been approved by the U.S. Food and Drug Administration?
"Bevacizumab scored a 1 on our safety scale, as the clinical trial is in its initial stages and existing data has yet to demonstrate established efficacy or patient security."
Is this research actively seeking to enroll participants?
"This particular clinical trial, which was initially posted on March 1st 2013 and last updated on April 6th 2022 is not presently recruiting candidates. Nevertheless, there are 1144 other medical studies actively searching for patients at the moment."
Has research ever been conducted related to the efficacy of Bevacizumab?
"Presently, 701 clinical trials for Bevacizumab are underway. Out of those studies, 205 have reached Phase 3. Notably, the bulk of these examinations are based in Taibei, Taiwan; however there are 38318 worldwide locations running such experiments."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger